A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome

Inclusion Criteria: * Patients aged18-75 years old (including the critical value), gender not limited; * Patients meeting the classification criteria of primary Sjogren's syndrome in ACR/EULAR 2016; * Patients with dry mouth VAS ≥4 and ESSDAI score \< 5; * Patients with positive autoantibodies (ANA or anti-SSA antibodies or anti-SSB antibodies or RF) and/or hyperimmunoglobulinemia or increased erythrocyte sedimentation rate; * Patients meeting the syndrome of qi and Yin deficiency in traditional Chinese medicine; * The subjects were informed and voluntarily signed the informed consent form. Exclusion Criteria: * Patients with a history of hypersensitivity or intolerance to any investigational therapeutic drug; * Patients diagnosed with secondary Sjogren's syndrome or combined with other connective tissue diseases; * Patients with severe lesions in the heart, brain, lungs, liver, kidneys, hematopoietic system, etc., as well as those with malignant tumors or infectious diseases; * Patients who are pregnant, preparing for pregnancy or breastfeeding; * Patients who have used cholinergic drugs or artificial tears/saliva in last 1 week; * Patients who have used hydroxychloroquine, total glycosides of Paeonia lactide, Iguratimod, cyclophosphamide, cyclosporine A, tacrolimus, and azathioprine in last 1 month; * Patients who have used glucocorticoids, methotrexate or mycophenolate mofetil in last 3 months; * Patients who have used Leflunomide in last 6 months; * Patients who have used rituximab in last 6 months, or have used other biological agents (such as tofacitinib) other than rituximab in last 3 months; * Patients who have participated in or are currently receiving any other experimental drugs or experimental medical devices within the past three months; * Other situations that researchers consider ineligible for inclusion (such as cognitive impairment, taking psychotropic drugs).